Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group - PubMed (original) (raw)
Clinical Trial
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
H Pehamberger et al. J Clin Oncol. 1998 Apr.
Abstract
Purpose: Patients with primary cutaneous melanoma with a Breslow thickness > or = 1.5 mm have only a 30% to 70% probability of survival after surgery, and no adjuvant therapy has so far improved this outcome. Since interferon alfa-2a (IFNalpha2a) exhibits antitumor activity in metastatic melanoma, we investigated whether adjuvant IFNalpha2a diminishes the occurrence of metastases and thus prolongs disease-free survival in melanoma patients after excision of the primary tumor.
Patients and methods: In a prospective randomized study, 311 melanoma patients with a Breslow thickness > or = 1.5 mm were assigned to either adjuvant IFNalpha2a treatment (n = 154) or observation (n = 157) after excision of the primary tumor. IFNalpha2a was given daily at a dose of 3 mIU subcutaneously (s.c.) for 3 weeks (induction phase), after which a dose of 3 mIU s.c. three times per week was given over 1 year (maintenance phase).
Results: Prolonged disease-free survival was observed in patients treated with IFNalpha2a versus those who underwent surgery alone. This difference was significant (P = .02) for all patients enrolled onto the study (intention-to-treat analysis) at a mean observation time of 41 months. Subgroup analysis showed that Breslow tumor thickness had no influence on treatment results in the groups of patients investigated.
Conclusion: Adjuvant IFNalpha2a treatment diminishes the occurrence of metastases and thus prolongs disease-free survival in resected primary stage II cutaneous melanoma patients.
Comment in
- Adjuvant interferon for stage II melanoma.
Haluska FG. Haluska FG. J Clin Oncol. 1998 Sep;16(9):3205-6. doi: 10.1200/JCO.1998.16.9.3205. J Clin Oncol. 1998. PMID: 9738597 No abstract available.
Similar articles
- Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial. - Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial. - Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Hansson J, et al. Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20. Lancet Oncol. 2011. PMID: 21256809 Clinical Trial. - [Adjuvant therapy of malignant melanoma].
Franke W, Neumann NJ, Ruzicka T, Schulte KW. Franke W, et al. Praxis (Bern 1994). 2001 Feb 22;90(8):301-6. Praxis (Bern 1994). 2001. PMID: 11256332 Review. German. - Multidisciplinary treatment of primary melanoma.
Yao K, Balch G, Winchester DJ. Yao K, et al. Surg Clin North Am. 2009 Feb;89(1):267-81, xi. doi: 10.1016/j.suc.2008.11.002. Surg Clin North Am. 2009. PMID: 19186240 Review.
Cited by
- Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study.
Zhu G, Shi Q, Zhao B, Liu Y, Feng T, Li C, Gao T. Zhu G, et al. J Cancer Res Clin Oncol. 2023 Aug;149(9):6263-6269. doi: 10.1007/s00432-023-04596-3. Epub 2023 Jan 30. J Cancer Res Clin Oncol. 2023. PMID: 36717393 - Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients.
Huang K, Xu Y, Gabriel EM, Misra S, Chen Y, Bagaria SP. Huang K, et al. J Skin Cancer. 2020 Oct 6;2020:5169051. doi: 10.1155/2020/5169051. eCollection 2020. J Skin Cancer. 2020. PMID: 33083061 Free PMC article. - A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.
Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE. Suarez-Kelly LP, et al. Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6. Cancer Immunol Immunother. 2019. PMID: 30725205 Free PMC article. Clinical Trial. No abstract available. - Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.
Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Oliver DE, et al. Melanoma Manag. 2018 Apr 9;5(1):MMT02. doi: 10.2217/mmt-2017-0025. eCollection 2018 Jun. Melanoma Manag. 2018. PMID: 30190928 Free PMC article. - Adjuvant Therapy for Melanoma.
Agha A, Tarhini AA. Agha A, et al. Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5. Curr Oncol Rep. 2017. PMID: 28417343 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical